| Data | Ora | Fonte | Titolo | Simbolo | Compagnia |
| 26/02/2024 | 14:30 | GlobeNewswire Inc. | LIXTE Biotechnology Enters into Exclusive Immune Oncology Patent License Agreement with NINDS and NCI | NASDAQ:LIXT | Lixte Biotechnology Holdings Inc |
| 29/01/2024 | 14:30 | GlobeNewswire Inc. | First Patient Dosed with LIXTE’s LB-100 and GSK’s Immunotherapy Dostarlimab-gxly in Ovarian Clear Cell Carcinoma Trial | NASDAQ:LIXT | Lixte Biotechnology Holdings Inc |
| 28/11/2023 | 23:21 | Edgar (US Regulatory) | Form 8-K - Current report | NASDAQ:LIXT | Lixte Biotechnology Holdings Inc |
| 13/11/2023 | 14:30 | GlobeNewswire Inc. | LIXTE Biotechnology Provides Update on Clinical Progress and Expanding Collaborations | NASDAQ:LIXT | Lixte Biotechnology Holdings Inc |
| 09/11/2023 | 23:16 | Edgar (US Regulatory) | Form 10-Q - Quarterly report [Sections 13 or 15(d)] | NASDAQ:LIXT | Lixte Biotechnology Holdings Inc |
| 16/10/2023 | 20:51 | Edgar (US Regulatory) | Form 4 - Statement of changes in beneficial ownership of securities | NASDAQ:LIXT | Lixte Biotechnology Holdings Inc |
| 16/10/2023 | 14:30 | GlobeNewswire Inc. | LIXTE, Netherlands Cancer Institute, and Oncode Institute to Expand Collaboration | NASDAQ:LIXT | Lixte Biotechnology Holdings Inc |
| 10/10/2023 | 21:55 | Edgar (US Regulatory) | Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material | NASDAQ:LIXT | Lixte Biotechnology Holdings Inc |
| 10/10/2023 | 21:47 | Edgar (US Regulatory) | Form DEF 14A - Other definitive proxy statements | NASDAQ:LIXT | Lixte Biotechnology Holdings Inc |
| 09/10/2023 | 14:30 | GlobeNewswire Inc. | LIXTE Biotechnology Holdings Announces the Passing of its Founder, John S. Kovach | NASDAQ:LIXT | Lixte Biotechnology Holdings Inc |
| 06/10/2023 | 02:39 | Edgar (US Regulatory) | Form 4/A - Statement of changes in beneficial ownership of securities: [Amend] | NASDAQ:LIXT | Lixte Biotechnology Holdings Inc |
| 29/09/2023 | 22:05 | Edgar (US Regulatory) | Form PRE 14A - Other preliminary proxy statements | NASDAQ:LIXT | Lixte Biotechnology Holdings Inc |
| 26/09/2023 | 14:30 | GlobeNewswire Inc. | LIXTE Appoints Bas van der Baan as President and Chief Executive Officer | NASDAQ:LIXT | Lixte Biotechnology Holdings Inc |
| 20/09/2023 | 14:30 | GlobeNewswire Inc. | LIXTE Biotechnology Announces a Supported Collaborative Trial to Study LIXTE’s First-in-Class PP2A Inhibitor, LB-100, Plus GSK’s Immunotherapy, Dostarlimab, in Clear-Cell Ovarian Cancer | NASDAQ:LIXT | Lixte Biotechnology Holdings Inc |
| 22/08/2023 | 06:15 | Edgar (US Regulatory) | Form EFFECT - Notice of Effectiveness | NASDAQ:LIXT | Lixte Biotechnology Holdings Inc |
| 11/08/2023 | 22:20 | Edgar (US Regulatory) | Form S-3 - Registration statement under Securities Act of 1933 | NASDAQ:LIXT | Lixte Biotechnology Holdings Inc |
| 01/08/2023 | 21:37 | Edgar (US Regulatory) | Form D - Notice of Exempt Offering of Securities | NASDAQ:LIXT | Lixte Biotechnology Holdings Inc |
| 20/07/2023 | 22:25 | Edgar (US Regulatory) | Form 424B5 - Prospectus [Rule 424(b)(5)] | NASDAQ:LIXT | Lixte Biotechnology Holdings Inc |
| 20/07/2023 | 22:05 | GlobeNewswire Inc. | LIXTE Biotechnology Announces Closing of $3.5 Million Registered Direct Offering and Concurrent Private Placement Priced At-the-Market under Nasdaq Rules | NASDAQ:LIXT | Lixte Biotechnology Holdings Inc |
| 18/07/2023 | 14:00 | GlobeNewswire Inc. | LIXTE Biotechnology Announces Pricing of $3.5 Million Registered Direct Offering and Concurrent Private Placement Priced At-the-Market under Nasdaq Rules | NASDAQ:LIXT | Lixte Biotechnology Holdings Inc |
| 17/07/2023 | 14:30 | GlobeNewswire Inc. | Preclinical Results of LIXTE Biotechnology’s Collaboration with Netherlands Cancer Institute Reveal Novel Mechanism by which LIXTE’s Lead Clinical Compound LB-100 Enhances Effectiveness of Immunotherapy and Chemotherapy | NASDAQ:LIXT | Lixte Biotechnology Holdings Inc |
| 26/06/2023 | 12:16 | Edgar (US Regulatory) | Current Report Filing (8-k) | NASDAQ:LIXT | Lixte Biotechnology Holdings Inc |
| 23/06/2023 | 14:30 | GlobeNewswire Inc. | LIXTE Biotechnology Holdings, Inc. Regains Compliance with Nasdaq Continued Listing Requirements | NASDAQ:LIXT | Lixte Biotechnology Holdings Inc |
| 07/06/2023 | 14:30 | GlobeNewswire Inc. | LIXTE Biotechnology and the Spanish Sarcoma Group Enroll First Patient in a Phase 1b/2 Randomized Trial of Doxorubicin +/- LIXTE’s Lead Anti-Cancer Compound, LB-100, in Advanced Soft Tissue Sarcomas | NASDAQ:LIXT | Lixte Biotechnology Holdings Inc |
| 02/06/2023 | 18:30 | GlobeNewswire Inc. | LIXTE Biotechnology Holdings, Inc. Announces 1-for-10 Reverse Stock Split of its Common Stock Effective on Pre-Market Opening on June 5, 2023 | NASDAQ:LIXT | Lixte Biotechnology Holdings Inc |
| 30/05/2023 | 14:30 | GlobeNewswire Inc. | Recently Published Independent Research Reveals New Mechanisms by Which LIXTE Biotechnology’s Lead Clinical Compound, LB-100, Increases Effectiveness of Cancer Immunotherapy | NASDAQ:LIXT | Lixte Biotechnology Holdings Inc |
| 10/05/2023 | 14:31 | Edgar (US Regulatory) | Quarterly Report (10-q) | NASDAQ:LIXT | Lixte Biotechnology Holdings Inc |
| 24/04/2023 | 14:30 | GlobeNewswire Inc. | LIXTE Biotechnology Reports First Spanish Site Activated to Begin Accrual of Patients for a Phase 1b/2 Clinical Trial of LIXTE's Lead Anti-Cancer Compound, LB-100, Added to Doxorubicin as First-Line Treatment of Advanced Soft Tissue Sarcoma | NASDAQ:LIXT | Lixte Biotechnology Holdings Inc |
| 04/04/2023 | 14:30 | GlobeNewswire Inc. | LIXTE Biotechnology Announces Sarah Cannon Research Institute Joins City of Hope’s Ongoing Phase 1b Clinical Trial in Evaluating Lixte’s Lead Anti-Cancer Compound, LB-100, in Small Cell Lung Cancer | NASDAQ:LIXT | Lixte Biotechnology Holdings Inc |
| 29/03/2023 | 14:32 | Edgar (US Regulatory) | Annual Report (10-k) | NASDAQ:LIXT | Lixte Biotechnology Holdings Inc |